{
    "Question": "Should patients with MTX-na√Øve and non-MTX csDMARDs exposed RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
    "Comparison": {
        "MTX monotherapy versus SSZ. ": {
            "filename": "PICO 2b_Comparison 2.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight",
                "b": "I2= 41%",
                "c": "Downgraded by one level due to serious indirectness. The evidence is based on a population who are non-MTX csDMARD naive.",
                "d": "Downgraded by one level due to serious imprecision. Small sample size.",
                "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size.",
                "f": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events.",
                "g": "I2= 44% ",
                "h": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
            }
        },
        " MTX monotherapy versus LEF. ": {
            "filename": "PICO 2b_Comparison 3.json",
            "Explanations": {
                "a": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm.",
                "b": "Downgraded by one level due to serious risk of bias. Lack of blinding of patients, personnel, and outcome assessors.",
                "c": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
            }
        },
        " SSZ versus HCQ. ": {
            "filename": "PICO 2b_Comparison 4.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment.",
                "b": "Downgraded by one level due to serious indirectness. The evidence is based on a non-MTX csDMARD-naive population.",
                "c": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Small sample size."
            }
        }
    },
    "References": {
        "1": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.",
        "2": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.",
        "3": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.",
        "4": "Nuver Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Annals of the Rheumatic Diseases. 1989;48(5):389.",
        "5": "Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.",
        "6": "Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.",
        "7": "Choi H, Seeger J, Kuntz K. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. Journal of Rheumatology. 2002;29(6):1156.",
        "8": "Maetzel A. Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis. Pharmacoeconomics. 2002;20(1):61-70."
    }
}